Aligos Therapeutics (ALGS) Change in Acquisitions & Divestments (2019 - 2026)

Aligos Therapeutics has reported Change in Acquisitions & Divestments for 8 years, with the latest figure at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 75.0% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $142.5 million (up 103.57% YoY), and the FY2025 full-year result was $127.5 million, up 41.67% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $35.0 million, down from $37.5 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $70.0 million in Q3 2025, with the low at $11000.0 in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $30.1 million across 5 years, with a median of $30.0 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 99.97% — and 2024, when it soared 272627.27%.
• Aligos Therapeutics' Change in Acquisitions & Divestments stood at $36.2 million in 2022, then tumbled by 99.97% to $11000.0 in 2023, then jumped by 181718.18% to $20.0 million in 2024, then surged by 87.5% to $37.5 million in 2025, then slipped by 6.67% to $35.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $35.0 million (Q1 2026), $37.5 million (Q4 2025), and $70.0 million (Q3 2025), per Business Quant data.